title: [Treatment of recurrent glioblastoma with single-agent bevacizumab].
abstract: BACKGROUND
  The prognosis of patients with recurrent glioblastoma is poor, as the median survival does not exceed 6 months.
  
  
  OBJECTIVE
  The aim of this study was to evaluate the efficacy of bevacizumab monotherapy in patients with recurrent glioblastoma multiforme.
  
  
  METHODS
  From April, 2012 to June, 2015, 40 patients with recurrent glioblastoma multiforme were treated with bevacizumab in a dose of 10 mg/kg every 2 weeks.
  
  
  RESULTS
  The average progression-free survival was 6.4 months (2-22 months), and the 6-month progression-free survival was 42.5%. The six-month overall survival was 82.5%, which corresponds to those published in the literature.
  
  
  CONCLUSIONS
  Bevacizumab monotherapy improves progression-free survival in patients with recurrent glioblastoma multiforme.
authors.affiliation: Fővárosi Onkoradiológiai Központ, Uzsoki Utcai Kórház, Semmelweis Egyetem Oktató Kórháza Budapest, Uzsoki u. 29., 1149.
authors.forename: Dániel
authors.initials: D
authors.lastname: Sinkó
authors.affiliation: Fővárosi Onkoradiológiai Központ, Uzsoki Utcai Kórház, Semmelweis Egyetem Oktató Kórháza Budapest, Uzsoki u. 29., 1149.
authors.forename: Csaba
authors.initials: C
authors.lastname: Nemeskéri
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000068258:Bevacizumab / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D005909:Glioblastoma / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D058990:Molecular Targeted Therapy / Q000379:methods*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D019233:Retreatment; D012189:Retrospective Studies; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab
keywords: bevacizumab; glioblastoma multiforme; progression-free survival; progressziómentes túlélés